PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study

Kim, Sung-Han; Park, Weon Seo; Park, Bo Ram; Joo, Jungnam; Joung, Jae Young; Seo, Ho Kyung; Chung, Jinsoo; Lee, Kang Hyun

doi:10.4103/1008-682x.180798

Cited by 16 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ki-67 appeared to be negative prognostic factor for patients' BRFS, but only in univariate analysis. In multivariate analysis however, we could not confirm its prognostic value which is in agreement with some authors results [9,10] though in disagreement with other studies where prognostic value of Ki-67, among others, but not hypoxic biomarkers were indicated [7]. We suggest, after other authors, that hypoxia in PCa might have more predictive power than proliferation [6].…”

Section: Discussioncontrasting

confidence: 95%

“…Also median time to BR of 35 (range 8.00-86.0) months was similar as in other reports after RP [7,9,13] or after RT (68.9%) [20]. Our study indicated that GS and pT stage were not useful predictive factors for BRFS which may be in agreement with some studies [6] although in contrast with other [7]. This discrepancy in the statistical power of clinicopathological variables maybe caused by different inclusion criteria in other studies, analysis of bigger patients population with advanced and G4 tumours, too short follow-up or use of different levels for PSA BR (np.…”

Section: Discussionsupporting

confidence: 90%

“…In our study cohort the median follow-up was 79 (range 12-148) months, and 10-year BRFS rate was 60% which is within the rage given by other authors [6,20,21]. Also median time to BR of 35 (range 8.00-86.0) months was similar as in other reports after RP [7,9,13] or after RT (68.9%) [20]. Our study indicated that GS and pT stage were not useful predictive factors for BRFS which may be in agreement with some studies [6] although in contrast with other [7].…”

Section: Discussionsupporting

confidence: 88%

“…In our cohort, the overall PSA recurrence rate was 32.3% which is within the range (25.1-41.0%) given by other authors [6,7,9,19]. In our study cohort the median follow-up was 79 (range 12-148) months, and 10-year BRFS rate was 60% which is within the rage given by other authors [6,20,21].…”

Section: Discussionsupporting

confidence: 83%

“…Early recognition based on biological markers could be helpful not only in identification of biological differences in benign and malignant lesions, offering further help in precise indication for more aggressive post-operative treatment (chemo/radiotherapy) but also for assessment of BR risk. Immunohistochemical expressions of many molecular tissue markers in PCa have been studied, such as: cyclooxygenase 2, P53, Ki-67, BCL2 and microvessel density [7][8][9], but their actual clinical usefulness has not yet been conclusively validated and approved for routine assessment [10]. In another study, BR was associated with tumour aggressive features in the DNA-based and RNA-based signatures to measure genomic instability [11].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Gasińska

Jaszczyński

Rychlik

et al. 2019

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The aim of the study was to evaluate prognosis for biochemical recurrence (BR) by analysing the pathological and biological characteristics of prostate cancer (PCa) after radical prostatectomy (RP). There were 130 men with clinically localized PCa in whom pretreatment serum PSA level and Ki-67, prostate specific membrane antigen (PSMA), glucose transporter-1 (GLUT-1), vascular endothelial growth factor (VEGF), microvessel density (MVD) and human telomerase reverse transcriptase (hTERT) proteins expression, based on number of immunohistochemically positive cells (labelling index), were retrospectively studied. In order to assess the prognostic significance of analysed variables in univariate and multivariate Cox analysis, patients were dichotomized based on cutoff points chosen by receiver operating characteristic (ROC) curves. There were 83 males (63.8%) at pT stage 1-2 and 47 (36.1%) at pT stage 3-4, respectively, with median (range) age of 62.8 years (49-77), and median followup of 78.5 months (12-148). In 42 (32.3%) men BR was found. In univariate analysis, tumour biological features: PSA ≤ 8 ng/ mL (p = 0.006), Ki-67LI ≤ 12.7% (p = 0.015), VEGFLI>11.0% (p = 0.030), and hTERTLI>6.7% (p = 0.016), but not clinicopathological parameters, appeared to be positive prognosticators for BRFS. In the Cox analysis, Ki-67 lost its significance, and clinicopathological parameters appeared to be nonsignificant. The independent negative prognostic factors for BRFS were: PSA > 8.0 ng/mL, (Hazard ratio = 2.75, p = 0.003), GLUT-1 > 19.1% (HR = 2.1, p = 0.032), VEGF≤11.0% (HR = 1, p = 0.024) and hTERT≤6.7% (HR = 1, p = 0.017). High PSA level, and GLUT-1 expression and lower VEGF and nuclear hTERT expression may indicate the great role of hypoxia in BR induction in PCa.

show abstract

Section: Discussioncontrasting

confidence: 95%

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Gasińska

Jaszczyński

Rychlik

et al. 2019

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki‐67, HIF‐1α and VEGF

Yang

Jing

et al. 2018

NMR in Biomedicine

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most common cancer in men. The Gleason score (GS) and biomarkers play important roles in the diagnosis and treatment of patients with PCa. The purpose of this study was to investigate the relationship between the apparent diffusion coefficient (ADC) and the molecular markers Ki-67, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in PCa. Thirty-nine patients with 39 lesions, who had been diagnosed with PCa, were enrolled in this study. All patients underwent diffusion-weighted magnetic resonance imaging (DW-MRI) (b = 800 s/mm ). The expression of Ki-67, HIF-1α and VEGF was assessed by immunohistochemistry. Statistical analysis was applied to analyze the association between ADC and prostate-specific antigen (PSA), GS and the expression of Ki-67, HIF-1α and VEGF. The group differences in ADC among different grades of Ki-67, HIF-1α and VEGF were also analyzed. The mean ± standard deviation of ADC was (0.76 ± 0.27) × 10 mm /s. ADC correlated negatively with PSA and GS (p < 0.05). The Ki-67 staining index (SI), HIF-1α expression and VEGF expression in PCa were correlated inversely with ADC, controlling for age (r = -0.332, p < 0.05; r = -0.662, p < 0.0005; and r = -0.714, p < 0.0005, respectively). ADC showed a significant difference among different grades of Ki-67 (F = 9.164, p = 0.005), HIF-1α (F = 40.333, p < 0.0005) and VEGF (F = 22.048, p < 0.0005). In conclusion, ADC was correlated with PSA, GS, and Ki-67, HIF-1α and VEGF expression in patients with PCa. ADC may be used to evaluate tumor proliferation, hypoxia and angiogenesis in PCa.

show abstract

Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67

Zhao,

Wei

et al. 2024

The Prostate

View full text Add to dashboard Cite

BackgroundKI67 is a well‐known biomarker reflecting cell proliferation. We aim to elucidate the predictive role of KI67 in the efficacy of abiraterone for patients with advanced prostate cancer (PCa).MethodsClinicopathological data of 152 men with metastatic PCa, who received abiraterone therapy were retrospectively collected. The KI67 positivity was examined by immunohistochemistry using the prostate biopsy specimen. The predictive value of KI67 on the therapeutic efficacy of abiraterone was explored using Kaplan–Meier curve and Cox regression analysis. The endpoints included prostate‐specific antigen (PSA) progression‐free survival (PSA‐PFS), radiographic PFS (rPFS), and overall survival (OS).ResultsIn total, 85/152 (55.9%) and 67/152 (44.1%) cases, respectively, received abiraterone at metastatic hormone‐sensitive (mHSPC) and castration‐resistant PCa (mCRPC) stage. The median KI67 positivity was 20% (interquartile range: 10%–30%). Overall, KI67 rate was not correlated with PSA response. Notably, an elevated KI67‐positive rate strongly correlated with unfavorable abiraterone efficacy, with KI67 ≥ 30% and KI67 ≥ 20% identified as the optimal cutoffs for prognosis differentiation in mHSPC (median PSA‐PFS: 11.43 Mo vs. 26.43 Mo, p < 0.001; median rPFS: 16.63 Mo vs. 31.90 Mo, p = 0.003; median OS: 21.77 Mo vs. not reach, p = 0.005) and mCRPC (median PSA‐PFS: 7.17 Mo vs. 12.20 Mo, p = 0.029; median rPFS: 11.67 Mo vs. 16.47 Mo, p = 0.012; median OS: 21.67 Mo vs. not reach, p = 0.073) patients, respectively. Multivariate analysis supported the independent predictive value of KI67 on abiraterone efficacy. In subgroup analysis, an elevated KI67 expression was consistently associated with unfavorable outcomes in the majority of subgroups. Furthermore, data from another cohort of 79 PCa patients with RNA information showed that those with KI67 RNA levels above the median had a significantly shorter OS than those below the median (17.71 vs. 30.72 Mo, p = 0.035).ConclusionsThis study highlights KI67 positivity in prostate biopsy as a strong predictor of abiraterone efficacy in advanced PCa. These insights will assist clinicians in anticipating clinical outcomes and refining treatment decisions for PCa patients.

show abstract

PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study

Cited by 16 publications

References 23 publications

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki‐67, HIF‐1α and VEGF

Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67

Contact Info

Product

Resources

About